<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and management of heart failure caused by hemodialysis arteriovenous access</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and management of heart failure caused by hemodialysis arteriovenous access</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation and management of heart failure caused by hemodialysis arteriovenous access</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barry A Borlaug, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald A Beathard, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Creation of a hemodialysis arteriovenous (AV) access (via constructed native AV fistula or a prosthetic AV graft) causes an acute decrease in systemic vascular resistance and a secondary increase in cardiac output [<a href="#rid1">1,2</a>]. The increased cardiac output is usually clinically insignificant but may rarely result in overt heart failure, particularly among patients with underlying heart disease. (See <a class="local">'Pathogenesis'</a> below.)</p><p>The pathogenesis, diagnosis, and management of hemodialysis AV access causing or exacerbating heart failure are presented in this topic review. High-output heart failure and the effects of hemodialysis AV access on pulmonary hypertension are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3462.html" rel="external">"Causes and pathophysiology of high-output heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/112442.html" rel="external">"Pulmonary hypertension in patients with end-stage kidney disease"</a>.)</p><p>A general discussion of myocardial dysfunction in the patient with end-stage kidney disease (ESKD) is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1846.html" rel="external">"Overview of screening and diagnosis of heart disease in patients on dialysis"</a>.)</p><p class="headingAnchor" id="H1804186413"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Heart failure and chronic kidney disease (CKD) are increasingly concurrent, especially in older patients and patients with hypertension, diabetes, or other cardiovascular comorbidities [<a href="#rid3">3</a>]. With the development of end-stage kidney disease (ESKD), the hemodynamic effects of a functioning hemodialysis arteriovenous (AV) access creates an additional burden on cardiac function and can cause or exacerbate heart failure [<a href="#rid1">1</a>]. Although the development of heart failure from the hemodynamic demands of hemodialysis AV access is predominantly limited to patients who have preexisting cardiovascular disease and/or cardiovascular risk factors, most patients on hemodialysis have cardiovascular disease or such risk factors. (See  <a class="medical medical_review" href="/z/d/html/1960.html" rel="external">"Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)"</a>.)</p><p>Heart failure is common among patients on hemodialysis; estimates of heart failure prevalence vary in this population but range between 30 and 70 percent [<a href="#rid4">4-8</a>]. However, limited data are available on the risk of hemodialysis access worsening or precipitating heart failure [<a href="#rid9">9-15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study involving 562 patients with CKD who had estimated glomerular filtration rate (eGFR) 30 to 59 mL/min/1.73 m<sup>2</sup>, 17 percent developed at least one episode of predialysis heart failure [<a href="#rid16">16</a>]. Among these patients, risk factors for acute heart failure included traditional risk factors (eg, diabetes, coronary artery disease, and prior history of heart failure) as well as the presence of functioning hemodialysis AV access [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 113 kidney transplant recipients who had previously undergone hemodialysis via hemodialysis AV access, 25.7 percent required hemodialysis AV access closure, primarily because of symptoms of heart failure [<a href="#rid17">17</a>]. The mean shunt flow among patients treated with shunt closure was 2197 mL/min compared with 851 mL/min among patients who did not undergo shunt closure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 214 patients on hemodialysis in which 122 (57 percent) were diagnosed with heart failure, 19 (9 percent) had high-output heart failure (defined by heart failure signs and symptoms plus a cardiac index &gt;3.9 L/min/m<sup>2</sup>); among these 19 patients, heart failure was attributed directly to high hemodialysis AV access flows in 11 (60 percent) [<a href="#rid8">8</a>].</p><p></p><p>Factors associated with hemodialysis AV access precipitating heart failure include development of right ventricular (RV) dilatation, left atrial dilation, development of atrial fibrillation, male sex, prior vascular access surgery, and high hemodialysis AV access flow rate (Qa) [<a href="#rid1">1</a>]. The risk of worsening heart failure is directly proportional to the flow of the hemodialysis AV access and is greater with worse pre-existing cardiac function [<a href="#rid18">18</a>]. There is no threshold Qa that defines risk. Even what is considered to be a normal flow may worsen or precipitate heart failure in patients with pre-existing heart failure or heart disease.</p><p>Similar rates of heart failure have been observed among patients with AV fistulas compared with those with AV grafts [<a href="#rid1">1,19</a>]. For AV fistulas, the risk of precipitating heart failure appears to be higher among patients who have an upper-arm AV fistula compared with forearm AV fistula [<a href="#rid11">11,16,17,20</a>]. The higher risk associated with upper-arm AV fistulas appears to be related to higher blood flow [<a href="#rid21">21</a>]. In a study including 96 patients with AV fistulas, 10 developed high-output cardiac failure after the AV fistula was placed [<a href="#rid11">11</a>]. </p><p>Significantly higher blood flow rates were seen in the upper-arm versus the forearm AV fistulas (1.58 versus 0.948 L/min) [<a href="#rid11">11</a>]. In the above cited observational study of 562 predialysis patients, the incidence of heart failure was much higher in patients who had a brachiocephalic AV fistula compared with those with a radial-cephalic AV fistula (40 versus 8 percent) [<a href="#rid16">16</a>].</p><p>Changes in flow over time in response to an AV access are discussed below. (See <a class="local">'Subacute and chronic changes'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The creation of a hemodialysis arteriovenous (AV) access results in acute, subacute, and chronic cardiovascular changes. Hemodialysis AV access causes an acute decrease in systemic vascular resistance and a secondary increase in cardiac output. Although usually clinically insignificant, the increased cardiac output causes heart failure in some patients, particularly those with underlying heart disease or hemodialysis AV access flows (Qa) greater than 2 L/min.</p><p></p><p class="headingAnchor" id="H2934006505"><span class="h2">Acute changes</span><span class="headingEndMark"> — </span>Acute effects of hemodialysis AV access creation include an immediate decrease in systemic vascular resistance and consequent increases in forward stroke volume, heart rate, and cardiac output.</p><p>The decrease in total peripheral vascular resistance is due to both changes in the vessels associated with the hemodialysis AV access (called access resistance [AR]) and changes in the systemic vessels (systemic vascular resistance). In response to increases in blood flow and shear stress, the vascular endothelium releases nitric oxide and other endothelium-dependent relaxing factors that dilate the artery, reducing shear stress towards normal [<a href="#rid22">22,23</a>]. One study showed that mean shear stress increased by 475 percent and brachial artery diameter by 15 percent within one day following placement of a radio-cephalic AV fistula [<a href="#rid24">24</a>].</p><p>The decrease in systemic vascular resistance causes an acute fall in both central and peripheral blood pressure. In response, there is an increase in sympathetic nervous system activity (which increases contractility and heart rate). It is this combination of decreased cardiac afterload and increased sympathetic activation that causes increases in cardiac output acutely [<a href="#rid11">11,22,25</a>].</p><p>The cardiac output increases immediately upon creation of the AV access and continues to increase over time [<a href="#rid11">11,20,26,27</a>]. This increase in cardiac output leads to an increase in venous return to the right side of the heart, leading to right ventricular dilatation in some patients [<a href="#rid1">1</a>]. Conversely, compression of an AV access over days and weeks increases systemic vascular resistance and blood pressure and decreases cardiac output. The increase in pressure leads to baroreflex-mediated reduction in heart rate (Branham's sign).</p><p class="headingAnchor" id="H4251361280"><span class="h2">Subacute and chronic changes</span><span class="headingEndMark"> — </span>Subacute changes occur within days after creation of the hemodialysis AV access. Within two weeks of AV access creation, blood volume increases, leading to greater venous return and increased right atrial, pulmonary artery, and left ventricular end-diastolic pressures [<a href="#rid28">28</a>]. Both plasma atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) concentrations increase after AV fistula creation, peaking 10 days after AV fistula creation [<a href="#rid29">29</a>].</p><p>The cardiac output continues to increase over days and weeks after creating an AV access [<a href="#rid11">11,20,26,27</a>]. In one study of 16 chronic kidney disease (CKD) patients, the cardiac output as assessed by echocardiography increased by 10 percent at 3 days and 14 percent by 14 days after AV fistula placement [<a href="#rid29">29</a>]. In another study of 30 patients, the cardiac output increased by 17 percent two weeks after successful AV fistula surgery [<a href="#rid22">22</a>].</p><p>The increase in cardiac output is generally proportional to hemodialysis Qa, although the relationship is complex [<a href="#rid11">11,20</a>]. Hemodialysis Qa is significantly lower for radiocephalic AV fistula compared with brachial-artery-based AV fistula [<a href="#rid30">30</a>]. In one study in which access blood flow was calculated just before the creation of an AV fistula and at days 1, 7, 28, and six months after construction, the most dramatic change occurred at day 1 [<a href="#rid31">31</a>]. By day 28, blood flow had doubled. A further 38.5 percent increase was noted at the last measurement performed after six months.</p><p>The increases in cardiac output over days and weeks after creation of an AV access may be one of many factors contributing to the observation that the highest mortality rate for incident hemodialysis patients occurs within the first 120 days after starting hemodialysis [<a href="#rid32">32,33</a>].</p><p>Chronic changes occurring over weeks and months in response to the AV access may include the development or worsening of right ventricular dilation and dysfunction, left ventricular hypertrophy (LVH), left atrial dilatation, and pulmonary hypertension [<a href="#rid1">1</a>]. Myocardial remodeling related to volume overload occurs within the first few weeks after AV access creation [<a href="#rid29">29,34,35</a>]. In some cases, left ventricle hypertrophy progresses despite improvements in fluid management and hypertension [<a href="#rid36">36-39</a>]. However, later data suggested that left ventricular chamber size decreased chronically after AV fistula creation, in contrast with the right ventricle, which dilates and may become dysfunctional [<a href="#rid1">1</a>].</p><p>Hemodialysis AV access-mediated increases in cardiac output can also increase the risk of pulmonary hypertension [<a href="#rid36">36-38</a>]. This issue is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/112442.html" rel="external">"Pulmonary hypertension in patients with end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H4102123684"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Symptoms and signs of heart failure may develop after hemodialysis arteriovenous (AV) access creation in patients with or without prior history of heart disease [<a href="#rid1">1,2</a>]. Such patients may show progressive symptoms including dyspnea at rest or with exertion, orthopnea, and fatigue that do not improve with aggressive diuresis or ultrafiltration (if on dialysis) to optimal dry weight or anemia correction. This may occur any time following creation of hemodialysis AV access, from weeks to even years later. It may be more difficult to achieve dry weight on hemodialysis because of intradialytic hemodynamic instability. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1945.html" rel="external">"Intradialytic hypotension in an otherwise stable patient", section on 'Decreased cardiac reserve'</a>.)</p><p>On physical examination, patients may present with tachycardia, edema, jugular venous distention, a wide pulse-pressure, an enlarged apical impulse, a midsystolic murmur (caused by increased ventricular filling), pulmonary crackles, peripheral edema, and warm extremities as a result of low systemic vascular resistance [<a href="#rid40">40</a>]. However, these dramatic findings of high-output failure may not be evident, and the physical examination may be relatively normal in some patients. (See  <a class="medical medical_review" href="/z/d/html/3462.html" rel="external">"Causes and pathophysiology of high-output heart failure"</a>.)</p><p class="headingAnchor" id="H2051807275"><span class="h1">MONITORING AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The evaluation of all patients following hemodialysis arteriovenous (AV) access includes an evaluation for heart failure. All patients who undergo access placement have markedly reduced kidney function and are at risk for heart failure. Patients who are at particular risk to develop heart failure related to the hemodialysis AV access include those with a large, distended AV fistula, especially in the upper-arm position [<a href="#rid1">1,2,9,11,33,40</a>].</p><p class="headingAnchor" id="H1703588965"><span class="h2">Monitoring strategy</span><span class="headingEndMark"> — </span>The optimal frequency of evaluation is not known. The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for Vascular Access: 2019 Update recommends regular physical examination or check of the AV access by a knowledgeable and experienced clinician to detect indicators of flow dysfunction [<a href="#rid41">41</a>]. We generally see patients in follow-up at four to six weeks after hemodialysis AV access creation and every four to eight weeks thereafter until the patient starts dialysis.</p><p class="bulletIndent1"><span class="glyph">●</span>We monitor for signs and symptoms of heart failure as a routine part of every visit and determine whether heart failure is present. (See <a class="local">'Approach to diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">An echocardiogram should be obtained when any new symptoms or signs suggestive of cardiac dysfunction develop. Echocardiographic findings suggesting the development of heart failure include dilation of the inferior vena cava, new right ventricular dilation or dysfunction, and increasing estimated pulmonary artery pressures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We examine the hemodialysis AV access at every visit. The presence of a large, distended AV fistula with very strong pulse augmentation and thrill is suspicious for high blood flow and should prompt a quantitative evaluation, particularly in the presence of heart failure signs and symptoms. (See <a class="local">'Examination and transient occlusion of AV access'</a> below and  <a class="medical medical_review" href="/z/d/html/1965.html" rel="external">"Clinical monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis", section on 'Intra-access blood flow monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/113760.html" rel="external">"Hemodialysis access-induced distal ischemia", section on 'High-flow arteriovenous fistulas'</a>.)</p><p></p><p class="bulletIndent1">A high-flow AV fistula can be defined as one with a volume flow (Qa) &gt;1.5 L/min. Patients with a Qa &gt;2 L/min are at increased risk for the development of heart failure [<a href="#rid11">11,20</a>]. Blood flow &gt;2 L/min may predict the occurrence of high-output heart failure [<a href="#rid11">11,42</a>]. However, Qa ≤2 L/min does not exclude hemodialysis AV access-induced heart failure. (See  <a class="medical medical_review" href="/z/d/html/113760.html" rel="external">"Hemodialysis access-induced distal ischemia", section on 'Quantifying arteriovenous access flow'</a>.)</p><p></p><p class="headingAnchor" id="H2993434255"><span class="h2">Approach to diagnosis</span><span class="headingEndMark"> — </span>For dialysis or predialysis chronic kidney disease (CKD) patients who have hemodialysis AV access and have signs or symptoms of heart failure, we perform a diagnostic evaluation to determine whether heart failure is present, as described separately. It should be noted that hemodialysis and peritoneal dialysis can mask signs and symptoms of heart failure by fluid removal. Evidence suggesting heart failure in these cases may be subtle, and symptoms may not be identified unless specific questions are asked. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1846.html" rel="external">"Overview of screening and diagnosis of heart disease in patients on dialysis", section on 'Diagnosis of heart failure'</a>.)</p><p>For dialysis or predialysis CKD patients who have hemodialysis AV access and are diagnosed with new-onset or worsening heart failure, we recommend obtaining a comprehensive echocardiogram (ie, with assessment of ejection fraction and cardiac output) and noninvasively measuring access blood flow. Methods for measurement of hemodialysis AV access blood flow are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1965.html" rel="external">"Clinical monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis", section on 'Intra-access blood flow monitoring'</a>.)</p><p>The presence of one or more of the following echocardiographic findings is suggestive of hemodialysis AV access-related heart failure: dilation of the inferior vena cava, right ventricular enlargement or dysfunction, elevation in estimated pulmonary artery pressures, or left ventricular enlargement. Of note, left ventricular ejection fraction can be normal or reduced in patients with hemodialysis AV access-related heart failure.</p><p>For patients with hemodialysis AV access with new or worsening heart failure with supportive findings on echocardiography, we suggest invasive evaluation of cardiac hemodynamics by right heart catheterization at rest and with transient AV access occlusion (30 seconds). This allows for definitive assessment of volume status, direct determination of cardiac output and pulmonary artery pressures, and examination of the hemodynamic response, which can provide valuable data when considering management strategies. Transient AV access occlusion should produce a reduction in cardiac output that is often coupled with reduction in central venous pressure. Pulmonary artery and pulmonary capillary wedge pressures may not decrease during transient AV access occlusion, due to the acute increase in cardiac afterload. (See <a class="local">'Examination and transient occlusion of AV access'</a> below.) </p><p>Some studies have suggested assessing the cardio-pulmonary recirculation (CPR) value, which is the ratio of hemodialysis Qa to the cardiac output (CO) in patients with hemodialysis Qa &gt;2 L/min. A Qa:CO ratio &gt;0.3 indicates a significant risk of developing high-output cardiac failure [<a href="#rid11">11,20,42</a>]. However, we do not rely on these indices, since a Qa:CO ratio ≤0.3 or a Qa ≤2 L/min does not exclude access-related heart failure.</p><p>We assess cardiac output indexed for body surface area (cardiac index [CI]) but do not use a threshold CI to identify a high-output state. Although high-output heart failure has traditionally been defined as symptoms in the setting of a cardiac output greater than 8 L/min or a CI greater than 4 L/min/m<sup>2</sup> [<a href="#rid2">2,43</a>], the use of a threshold value for CI is problematic since a CI that one patient may tolerate without problems may be excessive for another having decreased cardiac reserve. (See  <a class="medical medical_review" href="/z/d/html/1846.html" rel="external">"Overview of screening and diagnosis of heart disease in patients on dialysis"</a>.)</p><p>The diagnosis of heart failure due to the hemodialysis AV access is confirmed if improvement is observed with treatment [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H2267794773"><span class="h2">Examination and transient occlusion of AV access</span><span class="headingEndMark"> — </span>The presence of a large, distended hemodialysis AV fistula or AV graft with very strong pulse augmentation suggests high blood flow and should prompt an evaluation to determine effect of the access on systemic hemodynamics. When the hemodialysis AV access is transiently occluded (30 seconds), the degree of the arterial pulse increase (augmentation) distal to the AV anastomosis is proportional to the Qa. (See  <a class="medical medical_review" href="/z/d/html/97013.html" rel="external">"Early evaluation of the newly created hemodialysis arteriovenous fistula", section on 'Perform special maneuvers'</a>.)</p><p>Transient maximal occlusion (sphygmomanometer inflated to 50 mmHg above systolic pressure for 30 seconds) of a hemodynamically significant hemodialysis AV access usually decreases heart rate, raises arterial pressure, and lowers venous pressure; this has been termed the Nicoladoni-Branham sign [<a href="#rid45">45</a>]. The Nicoladoni-Branham sign has been shown to be related to arterial baroreceptor activation and increased arterial baroreflex sensitivity [<a href="#rid45">45</a>]. In addition to a decrease in heart rate, there is also an increase in arterial blood pressure and a decrease in cardiac output [<a href="#rid45">45-47</a>]. In a review of 17 patients, increases in systemic vascular resistance and mean arterial blood pressure during pneumatic occlusion of a surgical AV fistula were predictive of a reduction in left ventricular hypertrophy (LVH) after AV fistula ligation [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H3543690777"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of hemodialysis arteriovenous (AV) access-related heart failure includes other causes of heart failure (heart failure with preserved ejection fraction [HFpEF] or heart failure with reduced ejection fraction [HFrEF]), including other causes of high-output heart failure. For patients who develop new or worsening heart failure sometime after creation of hemodialysis access, clinical and echocardiographic evaluation should include evaluation for other potential causes of decompensation such as volume overload, left ventricular systolic dysfunction, and valve disease. The evaluation of causes of heart failure is discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a> and  <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/113041.html" rel="external">"Clinical manifestations, diagnosis, and management of high-output heart failure", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H1501537144"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The patient's cardiovascular status should be considered in choosing the dialysis modality, and it is one of the major criteria in selecting the appropriate vascular access type for patients undergoing hemodialysis [<a href="#rid30">30,40,41</a>]. Each patient should be classified using the New York Heart Association functional classification (NYHA classes I to IV) and the American College of Cardiology Foundation/American Heart Association stages of heart failure (ACC/AHA stages A to D) [<a href="#rid48">48,49</a>]. These classifications relate to patient prognosis and the risk associated with an arteriovenous (AV) fistula creation. Patients with end-stage kidney disease (ESKD) with NYHA functional class IV have the highest risk of clinical aggravation and fatal outcome after AV fistula creation [<a href="#rid30">30,40</a>].</p><p>Patients with heart failure may benefit more from peritoneal dialysis than in-center hemodialysis [<a href="#rid50">50-54</a>]. Peritoneal dialysis avoids the risks associated with AV access creation and allows better control of volume status because of daily ultrafiltration. However, many variables factor into the decision for peritoneal dialysis, including the patient's ability and willingness to perform the procedure. Although we believe all patients with heart failure should be evaluated for peritoneal dialysis, dialysis modality selection is based upon many factors. (See  <a class="medical medical_review" href="/z/d/html/1961.html" rel="external">"Management of heart failure in patients on dialysis", section on 'Dialysis modality'</a>.)</p><p>For patients with heart failure who are treated with hemodialysis, the following approach to vascular access selection in patients with ESKD and heart failure is suggested:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACC/AHA stage C heart failure with NYHA functional class I or II </strong>– Radial-cephalic AV fistula. A brachial artery-based AV fistula should be avoided because it carries the highest risk of worsening the cardiac performance. The best approach is to create a radial-cephalic AV fistula with sufficient blood flow to perform the hemodialysis treatment and, at the same time, with a minimum of hemodynamic impact. In addition, it has been suggested that an end-to-side anastomosis be used when creating a radial-cephalic AV fistula. This has been reported to result in a lower flow compared with a side-to-side anastomosis [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACC/AHA stage C with NYHA functional class III or IV or stage D </strong>– Tunneled hemodialysis catheter. For patients with advanced heart failure, insertion of a tunneled central venous hemodialysis access catheter rather than an AV fistula or graft is reasonable given the limited life expectancy for patients with higher stages of heart failure [<a href="#rid30">30</a>]. Patients who use a tunneled catheter are at high risk for infection and should be carefully followed for such. Alternatively, some experts would consider switching these patients from hemodialysis to peritoneal dialysis, although there are no data to support this approach. (See  <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management"</a>.)</p><p></p><p>These measures aim to avoid exposing a patient with heart failure to excessive blood flow. However, as discussed above, cardiac changes associated with the presence of an AV access occur within weeks to months even in the absence of what many would classify as excessive hemodialysis Qa, changes that have been associated with increased patient mortality [<a href="#rid55">55-57</a>] (see <a class="local">'Subacute and chronic changes'</a> above). </p><p>In addition, with the passage of time, patients without heart failure at baseline are at risk for developing heart failure. This raises the question as to whether flow reduction should be considered in patients with significant cardiac changes noted on echocardiography, even in the absence of clinical evidence of heart failure to prevent its development. In a study of 42 asymptomatic patients with cardiac changes, Qa reduction improved cardiac structure and function [<a href="#rid58">58</a>]. Although this was a small study, it suggested that the prevention of high Qa-induced complications is achievable through flow reduction. (See <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H4285282968"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>In the patient with hemodialysis arteriovenous (AV) access-related heart failure, management begins with control of volume status with dialysis and diuretics, correction of anemia, treatment of hypertension, and pharmacologic management of heart failure. (See  <a class="medical medical_review" href="/z/d/html/1846.html" rel="external">"Overview of screening and diagnosis of heart disease in patients on dialysis"</a>.)</p><p>If heart failure persists despite attempts to control it with medical therapy, we attempt to reduce the cardiac workload presented by the hemodialysis AV access. We use the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Close any unused AV access sites </strong>–<strong> </strong>If the patient has more than one hemodialysis AV access, one should be closed immediately while ensuring preservation of the best AV access to allow adequate kidney replacement therapy, and then reassess the patient's clinical status. Determination of whether the AV fistula is contributing to heart failure is described above. (See <a class="local">'Approach to diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/1913.html" rel="external">"Central vein obstruction associated with upper extremity hemodialysis access", section on 'Arteriovenous access occlusion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduce blood flow of the hemodialysis AV access that is used for hemodialysis, if heart failure persists (ie, with no unused fistulas) </strong>–<strong> </strong>To salvage the hemodialysis AV access, we try to reduce its blood flow before considering ligation unless heart failure is severe.</p><p></p><p class="bulletIndent1">Several different surgical techniques have been used to reduce AV fistula flow. The goal of surgery is to reduce AV access blood flow while maintaining sufficient flow for adequate dialysis. These techniques have included minimally invasive techniques using precision banding [<a href="#rid59">59-63</a>], and open surgical interventions, such as surgical banding or revision of the anastomosis or feeding artery [<a href="#rid64">64-66</a>]. (See  <a class="medical medical_review" href="/z/d/html/113760.html" rel="external">"Hemodialysis access-induced distal ischemia", section on 'High-flow arteriovenous fistulas'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study of 12 patients with a high-flow AV fistula and clinical signs of high-output heart failure, a precision banding procedure was effective for Qa reduction (see  <a class="medical medical_review" href="/z/d/html/113760.html" rel="external">"Hemodialysis access-induced distal ischemia", section on 'Precision banding'</a>) [<a href="#rid59">59</a>]. Adequacy of Qa restriction was evaluated intraoperatively using ultrasound flow measurements, adjusting the banding diameter in 0.5 mm increments to achieve the targeted AV fistula flow. Mean Qa was reduced to a mean of 598 mL/min (481 to 876) after banding. The clinical signs of heart failure disappeared, and AV fistulas remained patent in all patients. Two patients had kidney transplant failure and later successfully used the AV fistula. Follow-up postbanding was 1 to 18 months (mean = 12). In another study including 35 patients, AV fistula banding was associated with reductions in left ventricular (LV) size and pulmonary artery pressure as estimated by echocardiography [<a href="#rid1">1</a>]. While there was no reduction in right ventricular size in this study, there was no further progression in remodeling associated with banding. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another study, 17 hemodialysis patients with an upper-arm vascular access and heart failure were treated by ligating the brachial artery anastomosis and reconstructing the access using an expanded polytetrafluoroethylene vascular graft in a bypass from the radial artery (ie, revision using distal inflow [RUDI] procedure]) (see  <a class="medical medical_review" href="/z/d/html/113760.html" rel="external">"Hemodialysis access-induced distal ischemia", section on 'Revision using distal inflow'</a>) [<a href="#rid64">64</a>]. The mean access inflow rate and the mean cardiac output decreased after the inflow reduction procedure, with resolution of symptoms. The median length of follow-up in the series was 16 months. During the follow-up period, thrombosis or stenosis developed in seven patients, three of whom underwent surgical revision. Thirteen of the 17 accesses (77 percent) subjected to the inflow reduction procedure remained patent. Access loss was due to failed fistuloplasty or thrombosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a six-month prospective, observational study of 25 consecutive hemodialysis patients, there was a decrease in both eccentric and concentric hypertrophy after closure of an AV fistula and placement of a tunneled catheter [<a href="#rid67">67</a>]. The left ventricular ejection fraction also increased in this study. Improvement in cardiac function (and presumably heart failure severity) may be greater in patients with higher cardiac output prior to surgery [<a href="#rid68">68</a>]. Thus the degree to which patients improve may depend more on cardiac output rather than the degree of flow across the hemodialysis AV access site prior to surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>If refractory heart failure persists, close the AV access ─ </strong>If the approach defined above is ineffective in managing an AV fistula, we close the AV fistula and place a tunneled catheter or a small AV graft since the resistance is generally higher in AV grafts than fistulas. Given the clear association between heart failure development and the apparent irreversibility of at least some structural features, we would not attempt a lower flow AV fistula, for example, at the radial artery. Peritoneal dialysis may also be an option among some patients. (See  <a class="medical medical_review" href="/z/d/html/113760.html" rel="external">"Hemodialysis access-induced distal ischemia", section on 'Arteriovenous access ligation'</a>.)</p><p></p><p class="bulletIndent1">Evidence supporting the cardiac benefits of AV fistula closure comes from a trial in which 64 patients with a functional kidney transplant were randomly assigned to undergo AV fistula ligation or standard care (ie, no intervention) [<a href="#rid69">69</a>]. All patients underwent a cardiac magnetic resonance imaging prior to and six months following the ligation procedure (or no intervention in the control arm). At six months, LV mass was reduced by 22.1 g (95% CI, 15.0-29.1) in the AV fistula ligation group compared with a small increase of 1.2 g (95% CI, -4.8 to 7.2 g) in the control group. In addition, AV fistula ligation led to reductions in LV volume, RV volume, cardiac output, left atrial volume, and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels. The degree of reduction in LV mass was greater in patients with higher baseline cardiac output (ie, among patients with higher AV fistula flow), suggesting a dose-response effect [<a href="#rid70">70</a>]. None of the patients in this trial experienced allograft failure following closure, but a decline in kidney function following AV fistula closure was reported in another study [<a href="#rid71">71</a>]. While patients in this trial did not have a diagnosis of heart failure at baseline, the reductions in LV mass and volume are clinically meaningful and would be expected to be beneficial in patients with cardiac dysfunction or clinical heart failure.</p><p></p><p class="headingAnchor" id="H3479404960"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/132674.html" rel="external">"Society guideline links: Hemodialysis vascular access"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– Creation of hemodialysis arteriovenous (AV) access (via constructed native AV fistula or prosthetic AV graft) causes an acute decrease in systemic vascular resistance and a secondary increase in cardiac output. Although usually clinically insignificant, the increased cardiac output causes heart failure in some patients, particularly those with underlying heart disease or hemodialysis AV access flows greater than 2 L/min. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– Symptoms and signs of heart failure may develop weeks or years after hemodialysis AV access creation. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and diagnosis </strong>– Monitoring for and diagnosis of hemodialysis AV-access-related heart failure includes identification of at-risk patients, monitoring, identification of symptoms and signs of heart failure, diagnosis of heart failure, and identification of the cause of heart failure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of a large, distended hemodialysis AV fistula or AV graft with very strong pulse augmentation is suspicious for high blood flow and should prompt an evaluation for high-output heart failure. When the hemodialysis AV access is transiently occluded, the degree of the arterial pulse increase (augmentation) distal to the AV anastomosis is proportional to the Qa. (See <a class="local">'Examination and transient occlusion of AV access'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with hemodialysis AV access with new or worsening heart failure and supportive findings on echocardiography, we suggest invasive evaluation of cardiac hemodynamics by right heart catheterization at rest and with transient AV access occlusion. This allows for definitive assessment of volume status, direct determination of cardiac output and pulmonary artery pressures, and examination of the hemodynamic response to transient AV access occlusion. (See <a class="local">'Approach to diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– Regardless of heart failure risk or status, we place a distal radial-cephalic AV fistula rather than a brachial artery AV fistula, if possible. When creating an AV fistula, we generally use an end-to-side anastomosis since this has been reported to result in a lower flow compared with a side-to-side anastomosis. (See <a class="local">'Prevention'</a> above and  <a class="medical medical_review" href="/z/d/html/115151.html" rel="external">"Approach to the adult patient needing vascular access for chronic hemodialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications"</a>.)</p><p></p><p class="bulletIndent1">For patients with advanced heart failure (stage C with New York Heart Association [NYHA] functional class III or IV or stage D heart failure) despite optimum therapy), a tunneled hemodialysis catheter is an option given limited life expectancy and risk of access thrombosis due to low blood pressure. Alternatively, some experts would consider switching these patients from hemodialysis to peritoneal dialysis, although there are no data to support this approach. (See <a class="local">'Prevention'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>–<strong> </strong>For patients with AV-access related heart failure that remains uncontrolled despite medical therapy, we use the following approach: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Close any unused AV access sites and reassess the patient.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If heart failure remains refractory, reduce flow of the AV access that is used for hemodialysis and, if refractory heart failure persists, close the hemodialysis AV access. (See <a class="local">'Management'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reddy YNV, Obokata M, Dean PG, et al. Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. Eur Heart J 2017; 38:1913.</a></li><li><a class="nounderline abstract_t">Reddy YN, Melenovsky V, Redfield MM, et al. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol 2016; 68:473.</a></li><li><a class="nounderline abstract_t">House AA, Wanner C, Sarnak MJ, et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:1304.</a></li><li><a class="nounderline abstract_t">Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2380.</a></li><li><a class="nounderline abstract_t">Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47:884.</a></li><li><a class="nounderline abstract_t">Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38:992.</a></li><li><a class="nounderline abstract_t">Antlanger M, Aschauer S, Kopecky C, et al. Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis. Kidney Blood Press Res 2017; 42:165.</a></li><li><a class="nounderline abstract_t">Malik J, Valerianova A, Pesickova SS, et al. Heart failure with preserved ejection fraction is the most frequent but commonly overlooked phenotype in patients on chronic hemodialysis. Front Cardiovasc Med 2023; 10:1130618.</a></li><li><a class="nounderline abstract_t">MacRae JM, Pandeya S, Humen DP, et al. Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. Am J Kidney Dis 2004; 43:e17.</a></li><li><a class="nounderline abstract_t">Bednarek-Skublewska A, Jóźwiak L, Przywara S, et al. [Acute cardiac failure secondary to brachiocephalic arteriovenous fistula in patient on chronic haemodialysis]. Pol Arch Med Wewn 2004; 112:1221.</a></li><li><a class="nounderline abstract_t">Basile C, Lomonte C, Vernaglione L, et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant 2008; 23:282.</a></li><li><a class="nounderline abstract_t">Chapman F, Blackmur JP, Fotheringham J, et al. An uncommon cause of pleural effusions in a dialysis patient. Lancet 2012; 380:186.</a></li><li><a class="nounderline abstract_t">Ahearn DJ, Maher JF. Heart failure as a complication of hemodialysis arteriovenous fistula. Ann Intern Med 1972; 77:201.</a></li><li><a class="nounderline abstract_t">Engelberts I, Tordoir JH, Boon ES, Schreij G. High-output cardiac failure due to excessive shunting in a hemodialysis access fistula: an easily overlooked diagnosis. Am J Nephrol 1995; 15:323.</a></li><li><a class="nounderline abstract_t">Young PR Jr, Rohr MS, Marterre WF Jr. High-output cardiac failure secondary to a brachiocephalic arteriovenous hemodialysis fistula: two cases. Am Surg 1998; 64:239.</a></li><li><a class="nounderline abstract_t">Martínez-Gallardo R, Ferreira-Morong F, García-Pino G, et al. Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement. Nefrologia 2012; 32:206.</a></li><li><a class="nounderline abstract_t">Schier T, Göbel G, Bösmüller C, et al. Incidence of arteriovenous fistula closure due to high-output cardiac failure in kidney-transplanted patients. Clin Transplant 2013; 27:858.</a></li><li><a class="nounderline abstract_t">Amerling R, Ronco C, Kuhlman M, Winchester JF. Arteriovenous fistula toxicity. Blood Purif 2011; 31:113.</a></li><li><a class="nounderline abstract_t">Abbott KC, Trespalacios FC, Agodoa LY. Arteriovenous fistula use and heart disease in long-term elderly hemodialysis patients: analysis of United States Renal Data System Dialysis Morbidity and Mortality Wave II. J Nephrol 2003; 16:822.</a></li><li><a class="nounderline abstract_t">Wijnen E, Keuter XH, Planken NR, et al. The relation between vascular access flow and different types of vascular access with systemic hemodynamics in hemodialysis patients. Artif Organs 2005; 29:960.</a></li><li><a class="nounderline abstract_t">Caroli A, Manini S, Antiga L, et al. Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney Int 2013; 84:1237.</a></li><li><a class="nounderline abstract_t">Korsheed S, Eldehni MT, John SG, et al. Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol Dial Transplant 2011; 26:3296.</a></li><li><a class="nounderline abstract_t">Mitchell GF, Parise H, Vita JA, et al. Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension 2004; 44:134.</a></li><li><a class="nounderline abstract_t">Dammers R, Tordoir JH, Welten RJ, et al. The effect of chronic flow changes on brachial artery diameter and shear stress in arteriovenous fistulas for hemodialysis. Int J Artif Organs 2002; 25:124.</a></li><li><a class="nounderline abstract_t">GUYTON AC, SAGAWA K. Compensations of cardiac output and other circulatory functions in areflex dogs with large A-V fistulas. Am J Physiol 1961; 200:1157.</a></li><li><a class="nounderline abstract_t">Pandeya S, Lindsay RM. The relationship between cardiac output and access flow during hemodialysis. ASAIO J 1999; 45:135.</a></li><li><a class="nounderline abstract_t">Beigi AA, Sadeghi AM, Khosravi AR, et al. Effects of the arteriovenous fistula on pulmonary artery pressure and cardiac output in patients with chronic renal failure. J Vasc Access 2009; 10:160.</a></li><li><a class="nounderline abstract_t">Ori Y, Korzets A, Katz M, et al. Haemodialysis arteriovenous access--a prospective haemodynamic evaluation. Nephrol Dial Transplant 1996; 11:94.</a></li><li><a class="nounderline abstract_t">Iwashima Y, Horio T, Takami Y, et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40:974.</a></li><li><a class="nounderline abstract_t">Roca-Tey R. Permanent arteriovenous fistula or catheter dialysis for heart failure patients. J Vasc Access 2016; 17 Suppl 1:S23.</a></li><li><a class="nounderline abstract_t">Lomonte C, Casucci F, Antonelli M, et al. Is there a place for duplex screening of the brachial artery in the maturation of arteriovenous fistulas? Semin Dial 2005; 18:243.</a></li><li><a class="nounderline abstract_t">Bradbury BD, Fissell RB, Albert JM, et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007; 2:89.</a></li><li><a class="nounderline abstract_t">Roca-Tey R, Arcos E, Comas J, et al. Starting hemodialysis with catheter and mortality risk: persistent association in a competing risk analysis. J Vasc Access 2016; 17:20.</a></li><li><a class="nounderline abstract_t">London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002; 17 Suppl 1:29.</a></li><li><a class="nounderline abstract_t">Ori Y, Korzets A, Katz M, et al. The contribution of an arteriovenous access for hemodialysis to left ventricular hypertrophy. Am J Kidney Dis 2002; 40:745.</a></li><li><a class="nounderline abstract_t">Yigla M, Abassi Z, Reisner SA, Nakhoul F. Pulmonary hypertension in hemodialysis patients: an unrecognized threat. Semin Dial 2006; 19:353.</a></li><li><a class="nounderline abstract_t">Abassi Z, Nakhoul F, Khankin E, et al. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens 2006; 15:353.</a></li><li><a class="nounderline abstract_t">Nakhoul F, Yigla M, Gilman R, et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 2005; 20:1686.</a></li><li><a class="nounderline abstract_t">Banerjee D, Ma JZ, Collins AJ, Herzog CA. Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2007; 2:1186.</a></li><li><a class="nounderline abstract_t">Wasse H, Singapuri MS. High-output heart failure: how to define it, when to treat it, and how to treat it. Semin Nephrol 2012; 32:551.</a></li><li><a class="nounderline abstract_t">Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis 2020; 75:S1.</a></li><li><a class="nounderline abstract_t">Aitken E, Kerr D, Geddes C, et al. Cardiovascular changes occurring with occlusion of a mature arteriovenous fistula. J Vasc Access 2015; 16:459.</a></li><li><a class="nounderline abstract_t">Anand IS, Florea VG. High Output Cardiac Failure. Curr Treat Options Cardiovasc Med 2001; 3:151.</a></li><li><a class="nounderline abstract_t">Sidawy AN, Spergel LM, Besarab A, et al. The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access. J Vasc Surg 2008; 48:2S.</a></li><li><a class="nounderline abstract_t">Velez-Roa S, Neubauer J, Wissing M, et al. Acute arterio-venous fistula occlusion decreases sympathetic activity and improves baroreflex control in kidney transplanted patients. Nephrol Dial Transplant 2004; 19:1606.</a></li><li><a class="nounderline abstract_t">Bos WJ, Zietse R, Wesseling KH, Westerhof N. Effects of arteriovenous fistulas on cardiac oxygen supply and demand. Kidney Int 1999; 55:2049.</a></li><li><a class="nounderline abstract_t">Unger P, Wissing KM, de Pauw L, et al. Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients. Transplantation 2002; 74:73.</a></li><li class="breakAll">Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed., The Criteria Committee of the New York Heart Association (Ed), Little, Brown &amp; Co, Boston 1994. p.253.</li><li><a class="nounderline abstract_t">WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.</a></li><li><a class="nounderline abstract_t">Bertoli SV, Musetti C, Ciurlino D, et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int 2014; 34:64.</a></li><li><a class="nounderline abstract_t">Mehrotra R, Kathuria P. Place of peritoneal dialysis in the management of treatment-resistant congestive heart failure. Kidney Int Suppl 2006; :S67.</a></li><li><a class="nounderline abstract_t">Puttagunta H, Holt SG. Peritoneal Dialysis for Heart Failure. Perit Dial Int 2015; 35:645.</a></li><li><a class="nounderline abstract_t">Gotloib L, Fudin R, Yakubovich M, Vienken J. Peritoneal dialysis in refractory end-stage congestive heart failure: a challenge facing a no-win situation. Nephrol Dial Transplant 2005; 20 Suppl 7:vii32.</a></li><li><a class="nounderline abstract_t">Iadarola GM, Lusardi P, La Milia V, et al. Peritoneal ultrafiltration in patients with advanced decompensated heart failure. J Nephrol 2013; 26 Suppl 21:159.</a></li><li><a class="nounderline abstract_t">Paoletti E, De Nicola L, Gabbai FB, et al. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension. Clin J Am Soc Nephrol 2016; 11:271.</a></li><li><a class="nounderline abstract_t">Tripepi G, Benedetto FA, Mallamaci F, et al. Left atrial volume in end-stage renal disease: a prospective cohort study. J Hypertens 2006; 24:1173.</a></li><li><a class="nounderline abstract_t">Sharma R, Pellerin D, Gaze DC, et al. Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease. J Am Soc Echocardiogr 2006; 19:266.</a></li><li><a class="nounderline abstract_t">Valerianova A, Malik J, Janeckova J, et al. Reduction of arteriovenous access blood flow leads to biventricular unloading in haemodialysis patients. Int J Cardiol 2021; 334:148.</a></li><li><a class="nounderline abstract_t">Gkotsis G, Jennings WC, Malik J, et al. Treatment of High Flow Arteriovenous Fistulas after Successful Renal Transplant Using a Simple Precision Banding Technique. Ann Vasc Surg 2016; 31:85.</a></li><li><a class="nounderline abstract_t">Schneider CG, Gawad KA, Strate T, et al. T-banding: a technique for flow reduction of a hyperfunctioning arteriovenous fistula. J Vasc Surg 2006; 43:402.</a></li><li><a class="nounderline abstract_t">Zanow J, Petzold K, Petzold M, et al. Flow reduction in high-flow arteriovenous access using intraoperative flow monitoring. J Vasc Surg 2006; 44:1273.</a></li><li><a class="nounderline abstract_t">van Hoek F, Scheltinga M, Luirink M, et al. Banding of hemodialysis access to treat hand ischemia or cardiac overload. Semin Dial 2009; 22:204.</a></li><li><a class="nounderline abstract_t">Miller GA, Goel N, Friedman A, et al. The MILLER banding procedure is an effective method for treating dialysis-associated steal syndrome. Kidney Int 2010; 77:359.</a></li><li><a class="nounderline abstract_t">Chemla ES, Morsy M, Anderson L, Whitemore A. Inflow reduction by distalization of anastomosis treats efficiently high-inflow high-cardiac output vascular access for hemodialysis. Semin Dial 2007; 20:68.</a></li><li><a class="nounderline abstract_t">Parmar CD, Chieng G, Abraham KA, et al. Revision using distal inflow for treatment of heart failure secondary to arteriovenous fistula for hemodialysis. J Vasc Access 2009; 10:62.</a></li><li><a class="nounderline abstract_t">Bourquelot P. Access flow reduction for cardiac failure. J Vasc Access 2016; 17 Suppl 1:S60.</a></li><li><a class="nounderline abstract_t">Movilli E, Viola BF, Brunori G, et al. Long-term effects of arteriovenous fistula closure on echocardiographic functional and structural findings in hemodialysis patients: a prospective study. Am J Kidney Dis 2010; 55:682.</a></li><li><a class="nounderline abstract_t">Wohlfahrt P, Rokosny S, Melenovsky V, et al. Cardiac remodeling after reduction of high-flow arteriovenous fistulas in end-stage renal disease. Hypertens Res 2016; 39:654.</a></li><li><a class="nounderline abstract_t">Rao NN, Stokes MB, Rajwani A, et al. Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients. Circulation 2019; 139:2809.</a></li><li><a class="nounderline abstract_t">Rao NN, McDonald SP, Worthley MI, Coates PT. Response by Rao et al to Letter Regarding Article, "Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients". Circulation 2019; 140:e806.</a></li><li><a class="nounderline abstract_t">Weekers L, Vanderweckene P, Pottel H, et al. The closure of arteriovenous fistula in kidney transplant recipients is associated with an acceleration of kidney function decline. Nephrol Dial Transplant 2017; 32:196.</a></li></ol></div><div id="topicVersionRevision">Topic 1958 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329100" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470455" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : High-Output Heart Failure: A 15-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31053387" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149351" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7752588" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684552" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28395286" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37324637" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Heart failure with preserved ejection fraction is the most frequent but commonly overlooked phenotype in patients on chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15112194" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15773435" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : [Acute cardiac failure secondary to brachiocephalic arteriovenous fistula in patient on chronic haemodialysis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942475" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22794247" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : An uncommon cause of pleural effusions in a dialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4641654" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Heart failure as a complication of hemodialysis arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573191" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High-output cardiac failure due to excessive shunting in a hemodialysis access fistula: an easily overlooked diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9520814" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : High-output cardiac failure secondary to a brachiocephalic arteriovenous hemodialysis fistula: two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22425802" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24118251" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence of arteriovenous fistula closure due to high-output cardiac failure in kidney-transplanted patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21228578" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Arteriovenous fistula toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14736009" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Arteriovenous fistula use and heart disease in long-term elderly hemodialysis patients: analysis of United States Renal Data System Dialysis Morbidity and Mortality Wave II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16305651" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The relation between vascular access flow and different types of vascular access with systemic hemodynamics in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23715122" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21317408" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249547" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11908487" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The effect of chronic flow changes on brachial artery diameter and shear stress in arteriovenous fistulas for hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13710075" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Compensations of cardiac output and other circulatory functions in areflex dogs with large A-V fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10360711" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The relationship between cardiac output and access flow during hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19670168" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of the arteriovenous fistula on pulmonary artery pressure and cardiac output in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649659" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Haemodialysis arteriovenous access--a prospective haemodynamic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12407642" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26951899" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Permanent arteriovenous fistula or catheter dialysis for heart failure patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934972" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Is there a place for duplex screening of the brachial artery in the maturation of arteriovenous fistulas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699392" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26349859" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Starting hemodialysis with catheter and mortality risk: persistent association in a competing risk analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11812909" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Left ventricular alterations and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12324909" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The contribution of an arteriovenous access for hemodialysis to left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16970730" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pulmonary hypertension in hemodialysis patients: an unrecognized threat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775448" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840664" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942779" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217335" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High-output heart failure: how to define it, when to treat it, and how to treat it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32778223" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25634156" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cardiovascular changes occurring with occlusion of a mature arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11242561" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : High Output Cardiac Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19000589" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034165" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acute arterio-venous fistula occlusion decreases sympathetic activity and improves baroreflex control in kidney transplanted patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10231470" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of arteriovenous fistulas on cardiac oxygen supply and demand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12134102" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12134102" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23741058" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24179103" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Peritoneal ultrafiltration in refractory heart failure: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080114" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Place of peritoneal dialysis in the management of treatment-resistant congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26702006" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Peritoneal Dialysis for Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16024831" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Peritoneal dialysis in refractory end-stage congestive heart failure: a challenge facing a no-win situation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24307445" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Peritoneal ultrafiltration in patients with advanced decompensated heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26668021" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685218" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Left atrial volume in end-stage renal disease: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16500488" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33895210" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Reduction of arteriovenous access blood flow leads to biventricular unloading in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26616507" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of High Flow Arteriovenous Fistulas after Successful Renal Transplant Using a Simple Precision Banding Technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476625" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : T-banding: a technique for flow reduction of a hyperfunctioning arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145429" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Flow reduction in high-flow arteriovenous access using intraoperative flow monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19426430" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Banding of hemodialysis access to treat hand ischemia or cardiac overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20010547" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The MILLER banding procedure is an effective method for treating dialysis-associated steal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17244125" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Inflow reduction by distalization of anastomosis treats efficiently high-inflow high-cardiac output vascular access for hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19340803" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Revision using distal inflow for treatment of heart failure secondary to arteriovenous fistula for hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26951907" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Access flow reduction for cardiac failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089339" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term effects of arteriovenous fistula closure on echocardiographic functional and structural findings in hemodialysis patients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27225601" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cardiac remodeling after reduction of high-flow arteriovenous fistulas in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31045455" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31738596" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Response by Rao et al to Letter Regarding Article, "Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27798197" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The closure of arteriovenous fistula in kidney transplant recipients is associated with an acceleration of kidney function decline.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
